Kit B. Roes

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 125 publications

A NETwork meta-analysis with COST-effectiveness evaluation of pharmacological treatments for Heart Failure with Reduced Ejection Fraction: NET-COST-HFrEF.

A NETwork meta-analysis with COST-effectiveness evaluation of pharmacological treatments for Heart Failure with Reduced Ejection Fraction: NET-COST-HFrEF.

Journal: European journal of heart failure

Published: May 13, 2026

On the Two-Step Hybrid Design for Augmenting Randomized Trials Using Real-World Data.

On the Two-Step Hybrid Design for Augmenting Randomized Trials Using Real-World Data.

Journal: Statistics in biopharmaceutical research

Published: October 23, 2025

How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers.

How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers.

Journal: Cancer treatment reviews

Published: June 13, 2025

A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence.

A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence.

Journal: Pharmacoepidemiology and drug safety

Published: April 04, 2025

SIMPATHIC: Accelerating drug repurposing for rare diseases by exploiting SIMilarities in clinical and molecular PATHology.

SIMPATHIC: Accelerating drug repurposing for rare diseases by exploiting SIMilarities in clinical and molecular PATHology.

Journal: Molecular genetics and metabolism

Published: January 08, 2025

Optimizing Patient Registries for Regulatory Decision Making - Key Learnings From an HMA/EMA Multistakeholder Workshop.

Optimizing Patient Registries for Regulatory Decision Making - Key Learnings From an HMA/EMA Multistakeholder Workshop.

Journal: Clinical pharmacology and therapeutics

Published: December 05, 2024

Clinical Evidence 2030.

Clinical Evidence 2030.

Journal: Clinical pharmacology and therapeutics

Published: October 01, 2024

Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.

Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.

Journal: British journal of clinical pharmacology

Published: August 14, 2024

Ethnic differences in efficacy of drug treatment in patients with an acute manic episode: an individual patient data meta-analysis of randomized placebo-controlled trials.

Ethnic differences in efficacy of drug treatment in patients with an acute manic episode: an individual patient data meta-analysis of randomized placebo-controlled trials.

Journal: International journal of bipolar disorders

Published: August 07, 2024

Augmenting clinical trials in asthma through digital technology, decentralised designs, and person-centric endpoints: opportunities and challenges.

Augmenting clinical trials in asthma through digital technology, decentralised designs, and person-centric endpoints: opportunities and challenges.

Journal: The Lancet. Respiratory medicine

Published: July 10, 2024

Decision-Making Criteria and Methods for Initiating Late-Stage Clinical Trials in Drug Development From a Multi-Stakeholder Perspective: A Scoping Review.

Decision-Making Criteria and Methods for Initiating Late-Stage Clinical Trials in Drug Development From a Multi-Stakeholder Perspective: A Scoping Review.

Journal: Clinical pharmacology and therapeutics

Published: June 25, 2024

On the Concepts, Methods, and Use of "Probability of Success" for Drug Development Decision-Making: A Scoping Review.

On the Concepts, Methods, and Use of "Probability of Success" for Drug Development Decision-Making: A Scoping Review.

Journal: Clinical pharmacology and therapeutics

Published: June 20, 2024

Showing 1-12 of 125

Last Updated: 09/26/2026